伦瓦提尼
肝细胞癌
癌症研究
医学
体内
转录组
药理学
癌症
索拉非尼
ALDH2
二硫仑
脂肪变性
细胞周期蛋白E1
免疫疗法
肝癌
靶向治疗
肿瘤科
生物
生物信息学
生物标志物
体外
PALB2
作者
Bing Quan,Yongjiang Lu,Yining Cao,Shiping Chen,Yujie Shao,Jialiang Cai,Peiling Zhang,Yufan Cai,Guiqi Zhu,Biao Wang,Yi Yang,Junxian Du,Jian Zhou,Jia Fan,Zhang Yan,Jinghuan Li,Zhi Dai
标识
DOI:10.3350/cmh.2026.0743
摘要
Background/aims: Despite the rising global incidence of metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC), immunotherapy offers limited survival benefits in this non-viral etiology, positioning lenvatinib as a critical treatment that necessitates novel strategies to enhance its efficacy. This study aimed to identify MASLD-HCC signature genes and to explore a novel agent to overcome lenvatinib resistance. Methods: Single-cell RNA sequencing identified signature genes, validated by immunohistochemistry, qPCR, Western blot, and spatial transcriptomics in human and murine specimens. Virtual screening identified a natural compound targeting hub genes. Direct binding was confirmed using molecular dynamics simulations, cellular thermal shift assays, and surface plasmon resonance. Therapeutic efficacy and underlying mechanisms were comprehensively evaluated in vitro under lipotoxic stress conditions and in vivo using diet-induced orthotopic MASLD-HCC mouse models. Results: A 170-gene signature was established, with ABAT and ALDH2 prioritized as hub genes. Podocarpusflavone A (PCFA) emerged as a dual-targeting agent that robustly reverses acquired lenvatinib resistance. Instead of increasing protein abundance, PCFA directly binds these targets, which is accompanied by markedly enhanced cellular ABAT and ALDH activities. This diminishes the protective GABA shield and disrupts the mitochondrial NAD⁺ balance, precipitating a lethal mitochondrial superoxide burst and inhibiting key oncogenic pathways. In vivo, the PCFA and lenvatinib combination profoundly suppressed orthotopic tumor progression and was associated with short-term improvements in hepatic steatosis and fibrosis-related histological findings, with no evident toxicity under the conditions tested. Conclusions: PCFA combined with lenvatinib represents a promising strategy for MASLD-HCC and provides mechanistic insights into its antitumor activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI